Sentences with phrase «preserved ejection fraction»
The researchers were aware that prognosis of heart failure with preserved ejection fraction is poor.
http://aminoacidinformation.com/
Researchers (Y Omori, T Ohtani, et al), at the Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan, developed an animal study to analyze potential new treatments for heart failure — specifically heart failure with preserved ejection fraction (HFpEF) in hypertensive heart disease.
His team is now studying patients who have especially high risk of heart failure with preserved ejection fraction (HFpEF).
A large - scale metaanalysis on heart failure, using a huge individual patient dataset, found that diabetes was more frequent in women than men, including patients with both reduced and preserved ejection fraction (307).
A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long - term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as «diastolic heart failure» and congestive heart failure with reduced ejection fraction also known as «systolic heart failure.»
«There currently are no existing therapies to address the prognoses of the approximately 40 percent of patients with heart failure and a preserved ejection fraction,» said Eldrin Lewis, MD, advanced heart failure specialist, Brigham and Women's Hospital (BWH) Division of Cardiovascular Medicine, Department of Medicine, study co-author.
Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.
A late - breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function).
The TOPCAT trial is the first randomized, double - blind trial to assess the effect of spironolactone on clinical outcomes in these patients with heart failure and preserved ejection fraction.